Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Primary objective is to define the maximum tolerated dose (MTD) for the combination of AEB071
and BYL719. Secondary objectives are to define the safety and tolerability of AEB071 and
BYL719.